Hoth Therapeutics (HOTH) said Tuesday that its Alzheimer's drug, HT-ALZ, showed positive preclinical results by significantly lowering astrocyte activity in key brain areas of Alzheimer's model mice, potentially improving cognitive function.
The company said it plans to continue advancing HT-ALZ through additional studies and clinical trials.
It said it is currently conducting a secondary analysis to see if treatment affects the size or total number of astrocytes.
Shares of the company were up nearly 17% in recent Tuesday premarket activity.
Price: 1.1800, Change: +0.17, Percent Change: +16.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments